

Focus Area 14 *Title* Immunization and Infectious Diseases **Goal** Prevent disease, disability, and death from infectious diseases, including vaccine-preventable diseases.

| <i>Obj Num</i> | <i>Category</i> | <i>Objective</i> | <i>2010 US Target</i> | <i>Pop Cat</i> | <i>Population Description</i> | <i>Lead Agency</i> | <i>Level of Interest</i> | <i>Type of Interest</i> | <i>Modi- fied</i> | <i>Data Source</i> | <i>UT Baseline</i> | <i>UT Target</i> | <i>UT Target Selection</i> |
|----------------|--|---|-----------------------|----------------|-------------------------------|--------------------|--------------------------|-------------------------|-------------------|--------------------|--------------------|------------------|----------------------------|
| 14.01a | Diseases Preventable Through Universal Vaccination | Vaccine-preventable diseases - Congenital rubella syndrome (number of cases, children under 1 year) | 0 | main | | ELS(Epi) CFHS (im) | UDOH | S&I | NO | NETSS | 0 | 0 | HP2010 |
| 14.01b | Diseases Preventable Through Universal Vaccination | Vaccine-preventable diseases - Diphtheria (number of cases, ages under 35 years) | 0 | main | | ELS(Epi) CFHS (im) | UDOH | S&I | NO | NETSS | 0 | 0 | HP2010 |
| 14.01c | Diseases Preventable Through Universal Vaccination | Vaccine-preventable diseases - Haemophilus influenzae type b and unknown serotype - Children - (number of cases, children aged under 5 years) | 0 | main | | ELS(Epi) CFHS (im) | UDOH | S&I | NO | NETSS | 0 | 0 | HP2010 |
| 14.01d | Diseases Preventable Through Universal Vaccination | Vaccine-preventable diseases - Hepatitis B (number of cases, ages 2 to 18 years) | 9 | main | | ELS(Epi) CFHS (im) | UDOH | S&I | NO | NETSS | 4 | 0 | HP2010 |
| 14.01e | Diseases Preventable Through Universal Vaccination | Vaccine-preventable diseases - Measles (number of cases) | 0 | main | | ELS(Epi) CFHS (im) | UDOH | S&I | NO | NETSS | 3 | 0 | HP2010 |
| 14.01f | Diseases Preventable Through Universal Vaccination | Vaccine-preventable diseases - Mumps (number of cases) | 0 | main | | ELS(Epi) CFHS (im) | UDOH | S&I | NO | NETSS | 7 | 0 | HP2010 |
| 14.01g | Diseases Preventable Through Universal Vaccination | Vaccine-preventable diseases - Pertussis Children (number of cases, children aged under 7 years) | 2000 | main | | ELS(Epi) CFHS (im) | UDOH | S&I | NO | NETSS | 29 | 20 | HP2010 |
| 14.01h | Diseases Preventable Through Universal Vaccination | Vaccine-preventable diseases - Polio (wild-type virus) (number of cases) | 0 | main | | ELS(Epi) CFHS (im) | UDOH | S&I | NO | NETSS | 0 | 0 | HP2010 |

| | | | | | | | | | | | | |
|--------|--|---|------|------|--------------------|------|-----|----|-------|------------|------------|--------|
| 14.01i | Diseases Preventable Through Universal Vaccination | Vaccine-preventable diseases - Rubella (number of cases) | 0 | main | ELS(Epi) CFHS (im) | UDOH | S&I | NO | NETSS | 0 | 0 | HP2010 |
| 14.01j | Diseases Preventable Through Universal Vaccination | Vaccine-preventable diseases - Tetanus (number of cases, ages under 35 years) | 0 | main | ELS(Epi) CFHS (im) | UDOH | S&I | NO | NETSS | 0 | 0 | HP2010 |
| 14.01k | Diseases Preventable Through Universal Vaccination | Vaccine-preventable diseases - Varicella (chicken pox) (number of cases (thousands), ages 18 years and under) | 400 | main | ELS(Epi) CFHS (im) | UDOH | S&I | NO | NETSS | 74 | 50 | HP2010 |
| 14.02 | Diseases Preventable Through Universal Vaccination | Hepatitis B in infants and young children -Perinatal infections (number of cases, children aged under 2 years) | 400 | main | ELS(Epi) CFHS (im) | D/P | S&I | NO | NETSS | 4 cs<2 yrs | 0 cs<2 yrs | HP2010 |
| 14.03a | Diseases Preventable Through Universal Vaccination | Hepatitis B in adults and high-risk groups -Adults (cases per 100,000 population, ages 19 to 24 years) | 2.4 | main | ELS (Epi) | D/P | S&I | NO | NETSS | 2.04 | 0.02 | HP2010 |
| 14.03b | Diseases Preventable Through Universal Vaccination | Hepatitis B in adults and high-risk groups -Adults (cases per 100,000 population, ages 25 to 39 years) | 5.1 | main | ELS (Epi) | D/P | S&I | NO | NETSS | 2.6 | 0.65 | HP2010 |
| 14.03c | Diseases Preventable Through Universal Vaccination | Hepatitis B in adults and high-risk groups -Adults (cases per 100,000 population, ages 40 years and older) | 3.8 | main | ELS (Epi) | D/P | S&I | NO | NETSS | 2 | 0.5 | HP2010 |
| 14.03d | Diseases Preventable Through Universal Vaccination | Hepatitis B in adults and high-risk groups - High risk groups - Injection drug users (number of cases) | 1808 | main | ELS (Epi) | D/P | S&I | NO | NETSS | 7 | 2 | HP2010 |
| 14.03e | Diseases Preventable Through Universal Vaccination | Hepatitis B in adults and high-risk groups - High risk groups - Heterosexually active persons (number of cases) | 1240 | main | ELS (Epi) | D/P | S&I | NO | NETSS | 19 | 2 | HP2010 |

| | | | | | | | | | | | | |
|--------|--|--|------|------|--------------------|-----|-----|----|-------|----------|-----------|--------|
| 14.03f | Diseases Preventable Through Universal Vaccination | Hepatitis B in adults and high-risk groups - High risk groups - Men who have sex with men (number of cases) | 1808 | main | ELS (Epi) | D/P | S&I | NO | NETSS | 0 | 0 | HP2010 |
| 14.03g | Diseases Preventable Through Universal Vaccination | Hepatitis B in adults and high-risk groups - High risk groups - Occupationally exposed workers (number of cases) | 62 | main | ELS (Epi) | - | NS | - | - | NA | NA | HP2010 |
| 14.04 | Diseases Preventable Through Universal Vaccination | Bacterial meningitis in young children (new cases per 100,000 population, children 1 to 23 months) | 8.6 | main | ELS (Epi) | D/P | S&I | NO | NETSS | 12/100K | 7.9/100K | HP2010 |
| 14.05a | Diseases Preventable Through Universal Vaccination | Invasive pneumococcal infections - Children (new cases per 100,000 population, children aged under 5 years) | 46 | main | ELS (Epi) | D/P | S&I | NO | NETSS | 2.74 | 1.6 | HP2010 |
| 14.05b | Diseases Preventable Through Universal Vaccination | Invasive pneumococcal infections - Adults (new cases per 100,000 population, ages 65 years and older) | 42 | main | ELS (Epi) | D/P | S&I | NO | NETSS | 2.75 | 1.8 | HP2010 |
| 14.05c | Diseases Preventable Through Universal Vaccination | Invasive pneumococcal infections - Penicillin-resistant - Children (new cases per 100,000 population, children aged under 5) | 6 | main | ELS (Epi) | D/P | S&I | NO | NETSS | NA | NA | HP2010 |
| 14.05d | Diseases Preventable Through Universal Vaccination | Invasive pneumococcal infections - Penicillin-resistant - Adults (new cases per 100,000 population, ages 65 years and older) | 7 | main | ELS (Epi) | D/P | S&I | NO | NETSS | NA | NA | HP2010 |
| 14.06 | Diseases Preventable Through Targeted Vaccination | Hepatitis A - (new cases per 100,000 population) | 4.5 | main | ELS(Epi) CFHS (im) | D/P | S&I | NO | NETSS | 3.3/100K | 1.3/100K | HP2010 |
| 14.07 | Diseases Preventable Through Targeted Vaccination | Meningococcal disease - (new cases per 100,000 population) | 1 | main | ELS (Epi) | D/P | S&I | NO | NETSS | 0.3/100K | 0.25/100K | HP2010 |

| | | | | | | | | | | | | |
|-------|---|--|------|------|---------------|-----|-----|----|-------------------|----------|-----------|---------------|
| 14.08 | Diseases Preventable Through Targeted Vaccination | Lyme disease - In endemic States (new cases per 100,000 population) | 9.7 | main | ELS (Epi) | | NS | | | | | |
| 14.09 | Infectious Diseases and Emerging Antimicrobial Resistance | Hepatitis C - (new cases per 100,000 population) | 1 | main | ELS (Epi) | D/P | S&I | NO | NETSS | 0.6/100K | 0.25/100K | HP2010 |
| 14.10 | Infectious Diseases and Emerging Antimicrobial Resistance | Identification of persons with chronic hepatitis | DNC | main | ELS (Epi) | | NS | | | | | |
| 14.11 | Infectious Diseases and Emerging Antimicrobial Resistance | Tuberculosis - (new cases per 100,000 population) | 1 | main | ELS (HIV) | D/P | S&I | NO | TIMS | 2.3/100K | 0.8/100K | 75% REDUCTION |
| 14.12 | Infectious Diseases and Emerging Antimicrobial Resistance | Curative therapy for tuberculosis | 0.9 | main | ELS (HIV) | D/P | S&I | NO | TIMS | 0.74 | 0.9 | HP2010 |
| 14.13 | Infectious Diseases and Emerging Antimicrobial Resistance | Treatment for high-risk persons with latent tuberculosis infection | 0.85 | main | ELS (HIV) | D/P | S&I | NO | UNDER DEVELOPMENT | | 0.85 | HP2010 |
| 14.14 | Infectious Diseases and Emerging Antimicrobial Resistance | Timely laboratory confirmation of tuberculosis cases - Average number of days to report 75% of cases | 2 | main | ELS (HIV/LAB) | D/P | S&I | NO | TIMS | 17 DAYS | 12 DAYS | LAB STAFF |
| 14.15 | Infectious Diseases and Emerging Antimicrobial Resistance | Prevention services for international travelers | DNC | main | ELS (Epi) | | NS | | | | | |
| 14.16 | Infectious Diseases and Emerging Antimicrobial Resistance | Invasive early onset group B streptococcal disease (per 1,000 live births) | 0.5 | main | ELS (Epi) | | NS | | | | | |

[illegible]

[illegible]

| | | | | | | | | | | | | | |
|--------|-------------------------------------|---|------|--|---------------------|-------|---|--------------------------------|-----------------------|------|-----------|--|--|
| 14.24a | Vaccination Coverage and Strategies | Fully immunized young children and adolescents -Children 19 to 35 months | 0.8 | main | CFHS (im) | NS | | | | | | | |
| 14.24b | Vaccination Coverage and Strategies | Fully immunized young children and adolescents -Adolescents aged 13 to 15 years | DNC | main | ELS(Epi) CFHS (im) | NS | | | | | | | |
| 14.25a | Vaccination Coverage and Strategies | Providers who measure childhood vaccination coverage levels - Public health providers | 0.9 | main | CFHS (im) D/P | S&I | N | CDC | 6 (national baseline) | 0.9 | HP 2010 | | |
| 14.25b | Vaccination Coverage and Strategies | Providers who measure childhood vaccination coverage levels - Private providers | 0.9 | main | CFHS (im) | NS | | | | | | | |
| 14.26 | Vaccination Coverage and Strategies | Children participating in population-based immunization registries (children aged under 6 years) | 0.95 | main | CFHS (im) D/P | S | N | USIIS, CDC, NIP | 0.399 | 0.95 | HP 2010 | | |
| 14.27a | Vaccination Coverage and Strategies | Vaccination coverage among adolescents - 3 or more doses of hepatitis B (adolescents aged 13 to 15 years) | 0.9 | main | CFHS (im) D/P | S&I | N | Utah Annual School Report, CDC | 0.968 | 0.95 | HP 2010 | | |
| 14.27b | Vaccination Coverage and Strategies | Vaccination coverage among adolescents - 2 or more doses of measles, mumps, rubella (adolescents aged 13 to 15 years) | 0.9 | main | CFHS (im) | NS | | | | | | | |
| 14.27c | Vaccination Coverage and Strategies | Vaccination coverage among adolescents - 1 or more doses of tetanus-diphtheria booster (adolescents aged 13 to 15 years) | 0.9 | main | CFHS (im) | NS | | | | | | | |
| 14.27d | Vaccination Coverage and Strategies | Vaccination coverage among adolescents - 1 or more doses of varicella (excluding adolescents who have varicella) (adolescents aged 13 to 15 years) | 0.9 | main | CFHS (im) | NS | | | | | | | |
| 14.28a | Vaccination Coverage and Strategies | Hepatitis B vaccination among high-risk groups -Long-term hemodialysis patients | 0.9 | main | CFHS (im) | NS | | | | | | | |
| 14.28b | Vaccination Coverage and Strategies | Hepatitis B vaccination among high-risk groups -Men who have sex with men | 0.6 | main | CFHS (im) | NS | | | | | | | |
| 14.28c | Vaccination Coverage and Strategies | Hepatitis B vaccination among high-risk groups -Occupationally exposed workers | 0.98 | main | CFHS (im) | NS | | | | | | | |
| 14.29a | Vaccination Coverage and Strategies | Influenza and pneumococcal vaccination of high-risk adults - Noninstitutionalized adults -Influenza vaccine (age adjusted, ages 65 years and older) | 0.9 | main | CFHS (im) | NS | | | | | | | |
| 14.29a | Vaccination Coverage and Strategies | Influenza and pneumococcal vaccination of high-risk adults - Noninstitutionalized adults -Influenza vaccine (age adjusted, ages 65 years and older) | 0.9 | sub1 Adults Age 65+ with Diabetes Mellitus | CFHS (diabetes) D/P | S & I | N | Medicare/BR FSS | 0.465 | 0.9 | US Target | | |

| | | | | | | | | | | | | | | |
|--------|-------------------------------------|---|-----|------|---|-----------------|-----|-------|---|-----------------|-------|-----|-----------|--|
| 14.29b | Vaccination Coverage and Strategies | Influenza and pneumococcal vaccination of high-risk adults - Noninstitutionalized adults -Pneumococcal vaccine (age adjusted, ages 65 years and older) | 0.9 | main | | CFHS (im) | | NS | | | | | | |
| 14.29b | Vaccination Coverage and Strategies | Influenza and pneumococcal vaccination of high-risk adults - Noninstitutionalized adults -Pneumococcal vaccine (age adjusted, ages 65 years and older) | 0.9 | sub1 | Adults Age 65+ with Diabetes Mellitus | CFHS (diabetes) | D/P | S & I | N | Medicare/BR FSS | 0.241 | 0.9 | US Target | |
| 14.29c | Vaccination Coverage and Strategies | Influenza and pneumococcal vaccination of high-risk adults - Noninstitutionalized high-risk adults - Influenza vaccine (age adjusted, ages 18 to 64 years) | 0.6 | main | | CFHS (im) | | NS | | | | | | |
| 14.29c | Vaccination Coverage and Strategies | Influenza and pneumococcal vaccination of high-risk adults - Noninstitutionalized high-risk adults - Influenza vaccine (age adjusted, ages 18 to 64 years) | 0.6 | sub1 | Adults Age 18-64 with Diabetes Mellitus | CFHS (diabetes) | D/P | S & I | N | BRFSS | 0.445 | 0.6 | US Target | |
| 14.29d | Vaccination Coverage and Strategies | Influenza and pneumococcal vaccination of high-risk adults - Noninstitutionalized high-risk adults - Pneumococcal vaccine (age adjusted, ages 18 to 64 years) | 0.6 | main | | CFHS (im) | | NS | | | | | | |
| 14.29d | Vaccination Coverage and Strategies | Influenza and pneumococcal vaccination of high-risk adults - Noninstitutionalized high-risk adults - Pneumococcal vaccine (age adjusted, ages 18 to 64 years) | 0.6 | sub1 | Adults Age 18-64 with Diabetes Mellitus | CFHS (diabetes) | D/P | S & I | N | BRFSS | 0.23 | 0.6 | US Target | |
| 14.29e | Vaccination Coverage and Strategies | Influenza and pneumococcal vaccination of high-risk adults - Institutionalized - Influenza vaccine (ages 18 years and older) | 0.9 | main | | CFHS (im) | | NS | | | | | | |
| 14.29f | Vaccination Coverage and Strategies | Influenza and pneumococcal vaccination of high-risk adults - Institutionalized - Pneumococcal vaccine (ages 18 years and older) | 0.9 | main | | CFHS (im) | | NS | | | | | | |
| 14.30a | Vaccine Safety | Adverse events from vaccinations - Associated paralytic polio (number of VAPP | 0 | main | | CFHS (im) | | NS | | | | | | |
| 14.30b | Vaccine Safety | Adverse events from vaccinations - Febrile seizures caused by pertussis vaccines | 75 | main | | CFHS (im) | | NS | | | | | | |
| 14.31 | Vaccine Safety | Active surveillance for vaccine safety via large linked databases (number (millions)) | 13 | main | | CFHS (im) | | NS | | | | | | |